Neuronal decanoic acid oxidation is markedly lower than that of octanoic acid: A mechanistic insight into the medium-chain triglyceride ketogenic diet by Khabbush, A et al.
1 
 
Neuronal Decanoic Acid Oxidation is Markedly Lower than that of 
Octanoic Acid: a Mechanistic Insight into the Medium-Chain 
Triglyceride Ketogenic Diet  
Aziza Khabbush1, Michael Orford1, Yi-Chen Tsai2, Tricia Rutherford3, Maura 
O’Donnell3, Simon Eaton4* and Simon J R Heales1, 5, 6* 
 
1Genetics and Genomic Medicine, UCL Great Ormond Street Institute of Child Health, 
London, UK 
2Division of Colorectal Surgery, Department of Surgery, Kaohsiung Medical University 
Hospital, Kaohsiung, Taiwan 
3Vitaflo International, Liverpool, UK 
4Paediatric Surgery, UCL Great Ormond Street Institute of Child Health, London, UK 
5Chemical Pathology, Great Ormond Street for Children Hospital NHS Foundation Trust, 
London, UK 
6Neurometabolic Unit, National Hospital for Neurology and Neurosurgery, London, UK 
*The authors contributed equally 
Address correspondence to: Simon Heales, Chemical Pathology, Great Ormond Street 
Hospital Camelia Botnar Laboratories, Great Ormond Street for Children Hospital NHS 
Foundation Trust, Great Ormond Street, London, WC1N 3JH, UK. Email: 
Simon.Heales@gosh.nhs.uk; or Simon Eaton, Paediatric Surgery, UCL Great Ormond Street 
Institute of Child Health, 30 Guilford Street, London, WC1N 1EH, UK. Email: 
s.eaton@ucl.ac.uk  
 
Running title: Decanoic Acid Oxidation in Neurons 
Key Words: CPT1, epilepsy, drug-resistance, fatty acids, capric acid, caprylic acid  
No. of text pages: 14 
No. of words: 3422  
No. of references: 40  
No. of figures: 2 
No. of tables: 1 
2 
 
SUMMARY 
Objective: The medium chain triglyceride ketogenic diet contains both octanoic (C8) and 
decanoic (C10) acids. The diet is an effective treatment for pharmacoresistant epilepsy. Whilst 
the exact mechanism for its efficacy is not known, it is emerging that C10, but not C8, interacts 
with targets that can explain anti-seizure effects, e.g. peroxisome proliferator-activated 
receptor-γ (PPARγ) (eliciting mitochondrial biogenesis and increased antioxidant status) and 
the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor. For such effects 
to occur, significant concentrations of C10 are likely to be required in the brain.  
Methods: In order to investigate how this might occur, we measured the β-oxidation rate of 
13C-labelled C8 and C10 in neuronal SH-SY5Y cells using isotope-ratio mass spectrometry. The 
effects of carnitine palmitoyl transferase I (CPT1) inhibition, with the CPT1 inhibitor etomoxir, 
on C8 and C10 β-oxidation were also investigated.  
Results: Both fatty acids were catabolised, as judged by 13CO2 release. However, C10 was β-
oxidised at a significantly lower rate; 20% of C8. This difference was explained by a clear 
dependence of C10 on CPT1 activity, which is low in neurons, whereas 66% of C8 β-oxidation 
was independent of CPT1. In addition, C10 β-oxidation was decreased further in the presence 
of C8.  
Significance: It is concluded that, since CPT1 is poorly expressed in the brain, C10 is relatively 
spared from β-oxidation and can accumulate. This is further facilitated by the presence of C8 
in the MCT ketogenic diet, which has a sparing effect upon C10 β-oxidation.  
 
Key Words: CPT1, epilepsy, drug-resistance, fatty acids, capric acid, caprylic acid 
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INTRODUCTION 
The medium-chain triglyceride ketogenic diet (MCT KD) is frequently used as an effective 
treatment against drug-resistant epilepsy in children. A high fat, low carbohydrate regimen, 
the MCT KD induces ketone body production, pushing the body into ketosis thereby 
maintaining near normal plasma glucose levels due to provision of an alternative fuel source. 
During these shifts in metabolism, seizures are controlled in patients. Although ketone bodies 
have been postulated to play a therapeutic role, seizure control is poorly correlated with 
ketone body levels1,2. Thus, despite the relative success of the diet, the precise mechanism of 
action of the MCT KD remains unknown. However, there is a growing interest in the potential 
effects on seizures of the medium-chain octanoic (C8) and decanoic (C10) acids, which are 
known to accumulate in the plasma of patients receiving the MCT KD3,4.  
 
Despite both these fatty acids being present in the MCT KD and in patient plasma, evidence 
is now emerging to suggest that C10, and not C8, may be responsible for the beneficial effects 
associated with the MCT KD. Thus C10, and not C8, has previously been reported by us to 
elicit PPARγ-dependent increases in neuronal mitochondrial content, complex I and catalase 
activity5. These findings, coupled with the direct inhibitory effect of C10 on AMPA receptors6, 
provide mechanistic evidence whereby C10 could elicit seizure control. The anti-seizure 
properties of C10 are further supported by observations, in vivo, that report that mice fed 
with a C10-enriched chow display significantly improved seizure tolerance and brain 
antioxidant capacity7–11. In studies conducted by Wlaź et al., C10 levels were also determined 
in the brains of mice following C10-enriched feeding. Interestingly, the concentration of C10 
in mouse brain was found to average at 240-250μM, corresponding with therapeutic levels 
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reported in patient plasma on the MCT KD, as well as the optimum concentration (250µM) 
for mitochondrial proliferation in our previous studies5,12.  
 
Currently, MCT oils used in the MCT KD are varying mixtures of C8 and C10, the ratios of which 
differ from product to product13. This diet is generally favoured due to its ability to provide 
energy and generate ketones with a lower total fat intake compared to long-chain 
triglyceride-based diets thus improving palatability14,15. However, as medium-chain fatty acids 
are usually rapidly oxidised or converted to ketone bodies, how can sufficient levels of C10 
accumulate in the brain to permit the fatty acid to exert its effects on targets, such PPARγ and 
the AMPA receptor? To address this question, we here assessed the rates of β-oxidation of 
C8 and C10 in the human SH-SY5Y neuroblastoma cell line, i.e. following on from our previous 
work5. A well-characterised cell line, SH-SY5Y cells exhibit a range of neuron-like properties, 
providing a suitable model for this study. Furthermore, as C10 appears to be a key component 
with regards to understanding the mechanisms of the MCT KD, we also investigated whether 
C8 exerts any sparing effect concerning C10 β-oxidation.  
 
METHODS 
Materials 
Unless otherwise stated, all reagents were purchased from Sigma-Aldrich (Poole, UK). 
Dulbecco’s Modified Eagle’s Medium (DMEM)/Ham’s Nutrient Mixture (1:1), heat-inactivated 
foetal bovine serum (FBS) and 2.5 g/L trypsin-EDTA were purchased from ThermoFisher 
Scientific (Paisley, UK). Trypan Blue (0.4%) solution was purchased from Bio-Rad Laboratories 
Ltd (Hemel Hempstead, UK). Human neuroblastoma cell line, SH-SY5Y, was obtained from the 
European Collection of Cell Cultures (Public Health England, Salisbury, UK). Stable isotope-
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labelled compounds, [U-13C]glucose, [1-13C]decanoic acid ([1-13C]C10) and [1-13C]octanoic 
acid ([1-13C]C8) were purchased from Cambridge Isotopes Laboratories, Inc. via CK Isotopes 
(Ibstock, UK). [U-13C]palmitic acid ([U-13C]C16) was purchased from Larodan (Malmö, Sweden) 
and used as a 5:1 complex (molar ratio) with fatty acid-free bovine serum albumin. 
 
Cell culture  
SH-SY5Y cells were utilised between passages 20-24 for all experimental procedures. Cells 
were cultured in 1:1 DMEM/F12 medium, containing 17.5mM glucose and supplemented 
with 100ml/L heat-inactivated FBS and 10ml/L 200mM L-glutamine. All cells were maintained 
in a humidified atmosphere at 37°C and 5% CO2. Cells were subcultured by washing with 
10ml/flask Mg2+/Ca2+-free Dulbecco’s phosphate-buffered saline (DPBS), lifted with 2ml 
0.25% trypsin-EDTA and suspended in 8ml culture medium to inactivate the trypsin. The cell 
suspension was transferred to a falcon tube and centrifuged for 4 minutes at 500xg. The 
supernatant was removed and cells suspended in a known volume of fresh culture medium. 
Cells were counted using the Trypan Blue exclusion test for viability. A known volume of the 
cell suspension was mixed 1:1 with 0.4% Trypan Blue solution and counted with a Bio-Rad 
TC20™ Automated Cell Counter (Hemel Hempstead, UK). Cells were then seeded at a density 
of 1x104 cells/cm2 in 6-well plates, made up to a final volume of 2ml with fresh medium and 
cultured for 5 days prior to all experiments. The same starting number of cells was used for 
each investigation. Medium was refreshed every two days.  
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Glucose, C10 and C8 β-oxidation in SH-SY5Y cells 
All experimental procedures were carried out with the use of a specifically formulated DMEM 
medium, containing a final concentration of 15mM HEPES, 2.9mM sodium bicarbonate, 2mM 
L-glutamine, 0.5mM sodium pyruvate and 21.5µM phenol red. A stock solution of 134.3mM 
[U-13C]glucose was prepared by dissolving glucose in DMEM solution and then frozen at -20°C 
in aliquots. Stock solutions of 50mM [1-13C]decanoic acid ([1-13C]C10) and 50mM [1-13C]C8 
were prepared in DMSO, sterile-filtered and then stored in aliquots at -20°C. 
 
On day 5 of culture, complete growth medium was removed and cells washed once with 
DPBS. Cells were then incubated with 2ml of the DMEM formula, supplemented with 10% FBS 
and 3mM D-glucose, for 20h at 37°C and 5% CO2. After 20h, the medium was removed and 
cells washed once with DPBS. To each well, 3ml of DMEM was then added containing 3mM 
[U-13C]-glucose and vehicle control DMSO, or 3mM D-glucose with either 250µM [1-13C]C10 
or 250µM [1-13C]C8. Wells were then sealed with a 3ml layer of heavy mineral oil in order to 
prevent the loss of 13CO2 through gas exchange between the medium and the atmosphere16. 
Using this approach we were able to demonstrate negligible (<0.1%) loss of label from the 
medium. Cells were incubated at 37°C for 6 hours, with 100µl of medium sampled from each 
well at hourly intervals. Sampled medium were immediately stored in rubber-sealed 
Exetainer™ vials (Labco Ltd, Ceredigion, UK) and kept at -20°C until analysis. 
 
 
 
C10 and C8 co-incubation  
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The effects of co-incubating C10 and C8 on C10 β-oxidation in SH-SY5Y cells were also 
explored. Additional stock solutions of 25mM C8 and 100mM [1-13C]C10 were prepared in 
DMSO, sterile-filtered and stored in aliquots at -20°C. Cells were cultured and incubated for 
20h in 10% FBS-supplemented DMEM medium containing 3mM D-glucose, as previously 
described. Medium was then removed and cells washed. Medium was then replaced with 3ml 
DMEM containing either 3mM [U-13C]glucose and vehicle control DMSO, or 3mM unlabelled 
D-glucose. In each D-glucose-supplemented well, cells were treated with either a final 
concentration of 250µM [1-13C]C10, or 250µM [1-13C]C10 plus 62.5µM C8, at a fixed total 
volume. Wells were then sealed with heavy mineral oil, cells incubated and medium sampled 
as previously outlined.  
 
Preparation of [U-13C]-palmitic acid 
[U-13C]palmitic acid was neutralised with 0.35M NaOH and made to a concentration of 
17.5mM in water, before heating to 70°C until fully dissolved. Fatty acid-free bovine serum 
albumin (BSA) was then dissolved to a concentration of 3.5mM in water at 37°C. Swirling 
gently, [U-13C]-palmitate ([U-13C]-C16) was then slowly added 1:1 to BSA at 37°C, forming an 
8.75mM [U-13C]C16:BSA complex (5:1 molar ratio fatty acid:BSA). An additional stock solution 
of 1.75mM BSA in water was also prepared. Both solutions were aliquoted and stored at -
20°C until further use. 
 
CPT1 inhibition assay 
A stock solution of 50mM etomoxir was prepared in sterile cell culture grade water and stored 
in aliquots at -20°C. On day 5 of culture, growth medium was replaced with 2ml DMEM 
formula containing 3mM D-glucose and 10% FBS. Cells were incubated with or without the 
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presence of 50µM etomoxir, for 20h at 37°C and 5% CO2. Medium was then removed and 
replaced with 3ml DMEM, containing 3mM [U-13C]glucose and vehicle control DMSO or 3mM 
D-glucose with either 250µM [1-13C]C10, [1-13C]C8 or [U-13C]C16, with 50µM etomoxir also 
added to previously exposed cells. Wells were then sealed with heavy mineral oil, with cells 
incubated and medium sampled as previously described.  
 
Measurement of 13CO2 release   
Samples were thawed at room temperature and 100µl 1M hydrochloric acid was injected 
through the septum into each vial to release CO2 from the medium. Vials were centrifuged 
for 30 seconds at 500xg. Samples were then analysed on a GasBench II coupled to a Thermo 
Delta-XP isotope-ratio mass spectrometer (Thermo-Finnigan, Bremen, Germany). Ten repeat 
injections were carried out per sample, with 13CO2/12CO2 ratios measured against Vienna Pee 
Dee Belemnite (VPDB) using a calibrated CO2 reference gas. Following this, 13CO2/12CO2 ratios 
were then converted to mole percent excess using absolute molar ratio of 13C to 12C 
(0.0111796) in VPDB. The change in mole percent excess was then converted to pmol CO2 
generated using the volume of medium and concentration of bicarbonate (2.9mM) present, 
which was then corrected for the number of labelled carbon atoms (1 for C8 and C10, 6 for 
glucose and 16 for palmitate) to obtain pmol substrate oxidised. 
   
Cell viability  
Cells were incubated for 20h at 37°C and 5% CO2 with 50µM etomoxir in DMEM medium 
supplemented with 10% FBS, and then a further 6h at 37°C with 50µM etomoxir in DMEM 
medium without FBS. Cells were then lifted from wells with 1ml 0.25% trypsin-EDTA, 
suspended in 4ml culture medium and centrifuged for 4 minutes at 500xg. Supernatant was 
9 
 
removed and cells suspended in 1ml of fresh culture medium. Viability of cells was then tested 
using the Trypan Blue exclusion test. 
 
Statistical analysis 
Data are expressed as mean ± SD, with n number indicating the number of independent 
experiments carried out. Statistical analysis between two groups was performed using a 
Student’s t-test, whilst analysis of three groups or more was performed with one-way ANOVA, 
followed by a post-hoc Tukey’s test for multiple comparisons. Variables were considered to 
be statistically significant when p < 0.05.  
 
RESULTS 
β-oxidation rates of Glucose, C8 and C10 in SH-SY5Y cells  
13C-labelled compounds permit the measurement of cellular β-oxidation rates of glucose, C8 
or C10 via CO2 release emanating from pyruvate dehydrogenase activity and/or the TCA cycle.  
13CO2 release over 6 hours was used to determine and quantify the rate of cellular β-oxidation 
of each compound. Cells were treated with 3mM 13C-labelled glucose, in order to replicate 
physiological levels observed in patients under the MCT KD. 13C-labelled C10 and C8 were 
added separately to a final concentration of 250µM, this being the concentration of C10, 
previously determined by us5, for optimum effects upon mitochondria and antioxidant status. 
Furthermore, this replicates the brain concentration achieved following peripheral C10 
administration9,10. Unlabelled 3mM glucose was used in the presence of 13C-labelled C10 and 
C8.   
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13CO2 release, for each molecule studied, was linear for the 6 hour incubation. As expected, 
the rate of glucose oxidation was markedly faster than that of either C8 or C10 (Fig. 1A). 
However, C8 and C10 were found to be differentially oxidised in these cells, with C10 β-
oxidation significantly lower than that of C8, by approximately 80% (Fig. 1A). This suggests 
that C8 may be preferentially oxidised in SH-SY5Y cells. 
 
Effect of co-incubation of C8 and C10 on β-oxidation 
Current MCT KD preparations are composed of a mixture of C8 and C10 at varying ratios. In 
light of this, we examined the effects on [1-13C]C10 β-oxidation when SH-SY5Y cells were 
treated with 62.5µM unlabelled C8, reflecting the move towards a more C10-enriched 
formula, i.e. with C8 compromising only 20% of the total fatty acids. Despite the relatively low 
concentration, C8 addition was found to significantly impair the β-oxidation rate of C10 by 
29% (Fig. 1B).  
 
C10 β-oxidation following CPT1 inhibition 
To determine the mechanisms behind the differential β-oxidation of C8 and C10, the potential 
role of the carnitine shuttle was explored.  Whilst long chain fatty acids require this system, 
medium chain fatty acids are generally considered to be able to enter the mitochondrial 
matrix in a carnitine-independent manner17. Whilst this may be the case for C8, there are 
reports to suggest that C10, in contrast to C8, may require the carnitine system for complete 
mitochondrial β-oxidation18. Carnitine palmitoyltransferase I (CPT1) is responsible for 
transferring fatty acyl groups to carnitine and is the rate-limiting step in carnitine-dependent 
β-oxidation in mitochondria19–21. To evaluate the potential role of CPT1 in C8 and C10 β-
oxidation, the well-characterised CPT1 irreversible inhibitor etomoxir was used22–24. Through 
11 
 
dose-response experiments, [U-13C]palmitic (C16) acid, which is well-known to depend on 
CPT1 for mitochondrial β-oxidation, was used as a positive control to allow us to determine 
the maximal concentration (50 µM) of etomoxir that could be used to inhibit CPT1 without 
affecting cell viability (100µM etomoxir caused cell death as judged by trypan blue exclusion). 
With the conditions employed, β-oxidation of [U-13C]C16 was reduced by 99%, suggesting 
complete irreversible inhibition of CPT1 (Table 1). Moreover, etomoxir was observed to have 
no effect on viability of the SH-SY5Y cells used (data not shown). Under the same conditions, 
C10 β-oxidation was found to be reduced by 95% in the presence of etomoxir (Table 1), 
whereas C8 β-oxidation was only inhibited by 34%.  
DISCUSSION 
There is growing interest in the mode of action of the MCT KD and, in particular, with regards 
to the effects of the constituent medium-chain fatty acid, C10.  In contrast to C8, C10 appears 
to have a number of biological targets that can explain the anti-seizure properties of the diet. 
However, critical for C10 to exert its beneficial effects is attainment of a sufficiently high 
concentration within the brain. Existing data, including those generated from our own 
laboratory, suggest concentrations of up to 250µM C10 are required to facilitate an increase 
in mitochondrial biogenesis, increased antioxidant capacity and AMPA receptor 
inhibition5,6,12. However, such a concentration appears achievable, as oral administration of 
C10 to mice leads to brain concentrations of up to 250µM9,10. Medium-chain fatty acids are 
catabolised by β-oxidation resulting in acetyl CoA formation. This can be further metabolised 
to generate ketones and/or enter the TCA cycle. Since medium-chain fatty acids are able to 
cross the blood brain barrier25–27 and the enzymes of β-oxidation are reported to be present 
in neuronal cells28,29, we have in this study evaluated the ability of neuronal-like SH-SY5Y cells 
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to β-oxidise C8 and C10. We hypothesised that C10 would be relatively spared, which may 
result in a degree of accumulation of this fatty acid to occur. 
 
The use of 13C-labelled substrates allows for the metabolism of substrates to be compared, 
i.e. by capturing and quantifying the labelled CO2 released by the cells. Using this approach, 
metabolism of glucose was considerably greater than that for C8 or C10. This was expected, 
given that it is well established that glucose is the main fuel for neuronal energy 
metabolism30–33. Whilst showing lower rates of oxidation than glucose, both C8 and C10 were 
β-oxidised to some extent by the cells. However, our observation that C10 β-oxidation was 
markedly lower than that of C8 suggests that these two fatty acids are processed differently 
by SH-SY5Y cells. To ascertain the potential cause for this difference, we considered the 
involvement of the carnitine shuttle, as C10 is reported to utilise this system for maximal β-
oxidation to occur18. Furthermore, C10 oxidation is impaired in inherited disorders of 
carnitine metabolism34.  This reliance of C10 upon the carnitine shuttle is further supported 
here by our finding that CPT1 inhibition, by etomoxir, markedly impairs C10 β-oxidation, 
whereas C8 β-oxidation appeared mainly CPT1-independent.  Whilst etomoxir is a very well-
characterised CPT1 inhibitor, as reflected by its ability to almost completely abolish C16 β-
oxidation, it should be noted that it may have other targets, e.g. by acting as a PPARα agonist. 
Thus, relatively prolonged exposure (5 days) has been suggested to lead to up-regulation of 
fatty acid oxidation35. However, in our acute study, the converse was apparent, i.e. in keeping 
with CPT1 inhibition. Our finding that CPT1 inhibition markedly impairs C10 β-oxidation, 
whereas C8 β-oxidation was mainly CPT1-independent, supports the need for this system in 
neuronal type cells, i.e. if maximal catabolism of the fatty acid is to occur.     
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To further explore the potential common metabolic fates of C8 and C10, we looked at the 
effect of the presence of C8 on C10 β-oxidation. Even in the presence of a relatively low 
concentration of C8, C10 β-oxidation was significantly inhibited. This observation may suggest 
that in the MCT KD, the presence of C8 has a sparing effect to further limit the catabolism of 
C10 thus facilitating its accumulation in the brain and the manifestation of its anti-seizure 
effects. However, it is possible that other mechanisms could also contribute to the differential 
metabolism of C8 and C10, e.g. varying degrees of cellular uptake for the two fatty acids. 
Further studies, involving cellular fractionation following C8 and/or C10 exposure may 
therefore be informative  
 
To summarise, the data presented here suggest that in a neuronal cell line, C10 and C8 are 
differentially oxidised. Thus, C8 may be preferentially metabolised and provide energy, 
whereas, because of its requirement of the carnitine shuttle, C10 is metabolised at a lower 
rate and can consequently accumulate (Fig. 2). CPT1 activity in brain is low, and although 
there is also a brain-specific isoform of CPT1 (CPT1c), this isoform has not been found to 
demonstrate any significant enzymatic activity21,36–39. This hypothesis is further supported by 
the recent observation that reports, in astrocytes, that C8 is ketogenic whilst C10 is not40.  
 
In conclusion, the fatty acid components of the MCT KD are differentially metabolised by 
neuronal-like cells. The carnitine dependence and sluggish metabolism of C10 provides an 
explanation for how critical concentrations may occur and permit interaction with key anti-
seizure targets. In contrast, C8 may be preferentially metabolised and have two key effects: 
sparing of C10 by inhibiting C10 β-oxidation and acting as a fuel source for brain energy 
metabolism.  
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Whilst this study provides further mechanistic insight into the MCT KD, relevance to 
understanding the classical KD is not immediately clear. However, the possibility exists that 
progressive (mitochondrial/peroxisomal) oxidation of the long-chain fatty acid components 
occurs, leading to C10 formation and eventual neuronal C10 accumulation. Further work is 
clearly needed to test this hypothesis. Additional alternative mechanisms could also be 
responsible for efficacy of the classical KD.  
 
KEY POINTS  
 C10 β-oxidation is markedly lower than that of C8 in neuronal cells.  
 C10 β-oxidation is CPT1-dependent, whilst C8 is only partially so. 
 The presence of C8 significantly reduces C10 β-oxidation. 
 Low β-oxidation rates of C10 may lead to accumulation in brain and, consequently, 
anti-seizure effects. 
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Figure 1.  
A) Absolute oxidation rates of 13C-labelled 3mM glucose, 250µM C8 and 250µM C10 in SH-SY5Y cells 
per hour. The oxidation rate of [1-13C]C10 was found to be significantly lower than that of [U-
13C]glucose (***p < 0.001) and [1-13C]C8 (**p < 0.01). B) Effect of C8 co-incubation on β-oxidation of 
C10 in SH-SY5Y cells. The β-oxidation rate of 250µM [1-13C]C10 was significantly reduced (*p = 
0.0262) in the presence of 62.5µM unlabelled C8. Data are expressed as mean ± SD of 4 or 5 
independent experiments (n=4, n=5), each performed in 4 replicate wells.  
 
Oxidation rate (pmol/h) 
Compound - Etomoxir + Etomoxir 
[1-13C]C8 1139 ± 336 750 ± 200** 
[1-13C]C10 198 ± 75 10 ± 28*** 
[U-13C]C16 224 ± 105 2 ± 5*** 
 
Table 1.  
Effects of CPT1 inhibition on the β-oxidation rates of C8 and C10 in SH-SY5Y cells. Cells were pre-treated 
for 20h with the irreversible CPT1 inhibitor etomoxir (50µM) and then incubated for 6h with 13C-labelled 
250µM C8, C10, or C16:BSA in the presence of 50µM etomoxir. Control cells were processed identically 
but were pre-treated and incubated in the absence of etomoxir. CPT1 inhibition resulted in a significant 
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reduction (***p < 0.001 compared with untreated cells) in C10 β-oxidation by 95%. The β-oxidation 
rate of C8 was also significantly reduced by 34% (**p = 0.006 compared to untreated cells). Results are 
expressed as mean ± SD of 5 independent experiments (n=5), each performed in duplicate. CPT1 
inhibition was confirmed with a significant 99% inhibition of [U-13C]C16 oxidation (***p < 0.001 
compared to untreated cells). Results are expressed as mean ± SD of 3 independent experiments (n=3), 
each performed in duplicate. 
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Figure 2.  
C10 and C8 have differential effects with regards to potential seizure control, e.g. C10 acting as a 
PPARγ agonist, eliciting improvement in mitochondrial function. For this to occur, a sufficient 
neuronal concentration of C10 is required. It is proposed that due to its reliance on the carnitine 
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shuttle, β-oxidation of C10 is relatively slow, permitting accumulation of this fatty acid.  In contrast, 
C8 oxidation may proceed largely in the absence of the carnitine system, contributing to β-oxidation 
and cellular energy metabolism.  In addition, C8 may inhibit any C10 β-oxidation, further 
contributing to its accumulation.  
C8 acyl-coenzyme A (C8-CoA); C10 acyl-coenzyme A (C10-CoA); carnitine palmitoyltransferase I 
(CPT1); carnitine-acylcarnitine translocase (CAT); carnitine palmitoyltransferase II (CPT2), Outer 
mitochondrial Membrane (OMM), Inner mitochondrial membrane (IMM).   
